Recently, Pillay et al. [71] demonstrated that PARG inhibitor, PDD00017273, mimics poly(ADP-ribose) polymerase (PARP) inhibitor therapy in ovarian cancer cells by exacerbating the formation of hyperPARylated-PARP1 that severely compromises PARP activity. Here, PARP1 is linked to ovarian carcinoma.